Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Dose Finding Trial of MK-7075 in Proteus Syndrome
NCT02594215Phase 1Completed
- Sponsor
- National Human Genome Research Institute
- Start
- Nov 2015
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of miransertib in Proteus syndrome (PS), sponsored by National Human Genome Research Institute. Primary endpoints: Tissue drug levels, Tissue phospho-AKT level and 1 more. Started Nov 2015; status: completed.
02
Drugs
miransertib
03
Conditions
Proteus syndrome (PS)
Beyond the preview
Go deeper on NCT02594215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02594215.